Abstract
A significant proportion of patients with acute myeloid leukemia (AML) are unable to tolerate standard induction chemotherapy regimens. This is particularly true for patients who are of advanced age, have a poor performance status, and/or have significant medical comorbidities. Recent advances in understanding the genetic and molecular properties of AML have led to a spate of new treatment options for patients considered ineligible for standard chemotherapy. Here, we discuss these new treatment options, provide an overview of the completed and ongoing trials of the new agents, and highlight promising future directions in the treatment of AML in patients ineligible for intensive induction chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 526-535 |
| Number of pages | 10 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 19 |
| Issue number | 8 |
| State | Published - 1 Aug 2021 |